Clinical Trial Update: Circulating Tumor DNA (ctDNA) Monitoring in the Assessment and Prediction of the Efficacy of PARP Inhibitors (PARPi)

View source ↗

Summary

This entry notes a recruiting clinical trial evaluating circulating tumor DNA as a biomarker to assess and predict the efficacy of PARP inhibitors in metastatic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• PARP inhibitors

Snippet

Sponsor: Sun Yat-sen University | Conditions: Metastatic Castration-resistant Prostate Cancer | Status: RECRUITING